NPH Neuropharm

 

TIDMNPH 
 
RNS Number : 1133C 
Neuropharm Group PLC 
06 November 2009 
 

 
 
+-----------------------------------+------------------------------------+ 
| For immediate release             |                    6 November 2009 | 
+-----------------------------------+------------------------------------+ 
 
 
 
 
 
Neuropharm Group plc 
("Neuropharm" or the "Company") 
 
 
Posting of Annual Report & Accounts 
 
 
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on 
neurodevelopmental disorders, confirms that its Annual Report and Accounts for 
the year ended 30 June 2009 is today being posted to shareholders. 
 
 
An electronic copy of the Annual Report and Accounts is available on the 
Investors section of the Company's website, www.neuropharm.co.uk. 
 
 
 
 
 
 
For further information please contact: 
 
 
+-------------------------------------------+------------------------+ 
| Neuropharm                                |  + 44 (0) 1372 371 171 | 
+-------------------------------------------+------------------------+ 
| Robert Mansfield, Chief Executive Officer |                        | 
| Graham Yeatman, Chief Financial Officer   |                        | 
+-------------------------------------------+------------------------+ 
|                                           |                        | 
+-------------------------------------------+------------------------+ 
| Piper Jaffray Limited                     |  + 44 (0) 203 142 8700 | 
+-------------------------------------------+------------------------+ 
| Neil Mackison, Rupert Winckler            |                        | 
+-------------------------------------------+------------------------+ 
|                                           |                        | 
+-------------------------------------------+------------------------+ 
| Buchanan Communications                   |  + 44 (0) 207 466 5000 | 
+-------------------------------------------+------------------------+ 
| Mark Court                                |                        | 
+-------------------------------------------+------------------------+ 
 
 
 
 
Notes to Editors: 
 
 
About Neuropharm 
Neuropharm is a speciality pharmaceutical company focused on the development of 
products for the treatment and management of neurodevelopmental disorders. 
Please visit www.neuropharm.co.uk for further information. 
 
 
 
Rule 2.10 
 
 
In accordance with Rule 2.10 of the City Code on Takeovers and Mergers, the 
Company confirms that it has 31,536,697 ordinary shares of 10 pence each in 
issue and admitted to trading on the AIM market of the London Stock Exchange 
plc. The International Securities Identification Number for the ordinary shares 
is GB00B1NPJJ01. 
 
 
 
 
Dealing Disclosure Requirements 
 
 
Under the provisions of Rule 8.3 of the City Code on Takeovers and Mergers (the 
"Code"), if any person is, or becomes, "interested" (directly or indirectly) in 
1% or more of any class of "relevant securities" of Neuropharm, all "dealings" 
in any " relevant securities" of Neuropharm (including by means of an option in 
respect of, or a derivative referenced to, any such "relevant securities") must 
be publicly disclosed by no later than 3.30 pm (London time) on the London 
business day following the date of the relevant transaction. This requirement 
will continue until the date on which the offer becomes, or is declared, 
unconditional as to acceptances, lapses or is otherwise withdrawn or on which 
the "offer period" otherwise ends. If two or more persons act together pursuant 
to an agreement or understanding, whether formal or informal, to acquire an 
"interest" in "relevant securities" of Neuropharm, they will be deemed to be a 
single person for the purpose of Rule 8.3. 
 
 
Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant 
securities" of Neuropharm by Neuropharm or by any of its "associates", must be 
disclosed by no later than 12.00 noon (London time) on the London business day 
following the date of the relevant transaction. 
 
 
A disclosure table, giving details of the companies in whose "relevant 
securities" "dealings" should be disclosed, and the number of such securities in 
issue, can be found on the Takeover Panel's website at 
www.thetakeoverpanel.org.uk. 
 
 
"Interests in securities" arise, in summary, when a person has long economic 
exposure, whether conditional or absolute, to changes in the price of 
securities. In particular, a person will be treated as having an "interest" by 
virtue of the ownership or control of securities, or by virtue of any option in 
respect of, or derivative referenced to, securities. 
 
 
Terms in quotation marks are defined in the Code, which can also be found on the 
Panel's website. If you are in any doubt as to whether or not you are required 
to disclose a "dealing" under Rule 8, you should consult the Panel. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 ACSBBBDBCGGGGCL 
 

Neuropharm (LSE:NPH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024

Neuropharm (LSE:NPH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024